Cholinesterase inhibitors for Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics
Journal Title: Archives of Medical Science - Year 2007, Vol 3, Issue 1
Abstract
Introduction: Considering lack of accepted guideline in cases of Parkinson’s disease-related visual hallucinations with poor response or intolerance to antipsychotics, and their possible cholinergic pathogenesis, the trial with cholinesterase inhibitors seems to be legitimated. Material and methods: Five patients with PD (with or without dementia) complicated by VH and unresponsive to atypical antipsychotics were offered a 12-week, open-label trial of a cholinesterase inhibitor. Results: All 5 subjects completed the trial with no major adverse effects and, noteworthy, no discontinuations due to adverse events. VH resolved in 4 subjects and were markedly diminished in one person. Neither changes in UPDRS scores nor exaggeration of subjective complaints about extrapyramidal symptoms were noted during treatment. Conclusions: Cholinesterase inhibitors, rivastigmine or donepezil, might represent a useful alternative to antipsychotics for patients with PD accompanied by VH even in the absence of dementia.
Authors and Affiliations
Tomasz Sobow
Keywords
Related Articles
- EP ID EP154668
- DOI -
- Views 181
- Downloads 0
From Editor-in-Chief<br /> Impact Factor 2009 – the main aim of Archives of Medical Science
Haptoglobin polymorphism correlated with coronary artery disease
Early outcome of aortic valve replacement with mechanical prosthesis in patients with aortic stenosis. Is patient-prosthesis mismatch a significant clinical problem?
Introduction: Prevalence of aortic valve disease increases with a population’s aging. Aortic valve replacement (AVR) is one of the most frequently performed procedures in cardiac surgery centres. Patient-prosthesis misma...
Diagnostic and prognostic value of telomerase assay in lung cancer
Breast cancer in pregnant women: report of two cases and review of the literature